We are live on ! Find out more
DP

DSAM Partners Portfolio holdings

AUM $176M
1-Year Est. Return 83.78%
This Fund
S&P 500
This Quarter Est. Return
+37.02%
1 Year Est. Return
+83.78%
3 Year Est. Return
+343.2%
5 Year Est. Return
+1,202.92%
10 Year Est. Return
AUM
$854M
AUM Growth
+$277M
Cap. Flow
+$130M
Cap. Flow %
15.2%
Top 10 Hldgs %
41.7%
Holding
70
New
33
Increased
12
Reduced
13
Closed
12

Top Buys

Rank Stock Value
1
MU icon
Micron Technology
MU
+$38.8M
2
VNT icon
Vontier
VNT
+$27M
3
EXPE icon
Expedia Group
EXPE
+$20.5M
4
QRVO icon
Qorvo
QRVO
+$18.4M
5
CCK icon
Crown Holdings
CCK
+$16.9M

Sector Composition

Rank Sector Weight
1 Technology 30.72%
2 Consumer Discretionary 15.26%
3 Healthcare 13.4%
4 Industrials 12.59%
5 Communication Services 10.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GCMG icon
26
GCM Grosvenor
GCMG
$749M
$13.3M 1.56%
+1,000,000
New +$11.1M
META icon
27
Meta Platforms (Facebook)
META
$1.51T
$13.2M 1.55%
48,500
-90,599
-65% -$24.8M
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$344M
$13.1M 1.54%
239,703
+60,073
+33% +$2.19M
PDD icon
29
Pinduoduo
PDD
$122B
$12.4M 1.45%
+69,786
New +$8.34M
ON icon
30
ON Semiconductor
ON
$32.9B
$11.6M 1.36%
+353,942
New +$9.88M
AR icon
31
Antero Resources
AR
$10.6B
$11.4M 1.33%
+2,088,824
New +$8.57M
INMD icon
32
InMode
INMD
$895M
$11.2M 1.31%
472,116
-268,862
-36% -$5.68M
BOAC.U
33
DELISTED
Bluescape Opportunities Acquisition Corp. Units, each consisting of one Class A ordinary share, and one-half of one redeemable warrant
BOAC.U
$11.2M 1.31%
+1,000,000
New +$10.5M
DIS icon
34
Walt Disney
DIS
$171B
$10.5M 1.23%
+58,000
New +$8.32M
CVNA icon
35
Carvana
CVNA
$45.1B
$10.4M 1.22%
+217,530
New +$9.94M
VRTX icon
36
Vertex Pharmaceuticals
VRTX
$124B
$9.33M 1.09%
+39,477
New +$9.06M
RUN icon
37
Sunrun
RUN
$2.26B
$8.73M 1.02%
+125,798
New +$7.81M
SMAR
38
DELISTED
Smartsheet Inc.
SMAR
$8.59M 1%
+123,895
New +$7.26M
HRTX icon
39
Heron Therapeutics
HRTX
$88.9M
$7.43M 0.87%
351,158
+89,852
+34% +$1.56M
BBIO icon
40
BridgeBio Pharma
BBIO
$16.5B
$7.11M 0.83%
+99,937
New +$4.82M
KRON
41
DELISTED
Kronos Bio
KRON
$5.98M 0.7%
+200,096
New +$6.28M
MLM icon
42
Martin Marietta Materials
MLM
$34.8B
$5.37M 0.63%
18,915
+11,346
+150% +$3.02M
OPEN icon
43
Opendoor
OPEN
$3.69B
$5.33M 0.62%
+242,547
New +$5.09M
ALLO icon
44
Allogene Therapeutics
ALLO
$570M
$5.27M 0.62%
208,798
+25,798
+14% +$841K
KRYS icon
45
Krystal Biotech
KRYS
$10.5B
$5.26M 0.62%
+87,608
New +$4.38M
MNTS icon
46
Momentus
MNTS
$86.1M
$4.94M 0.58%
+22
New +$3.45M
VMC icon
47
Vulcan Materials
VMC
$37.3B
$4.84M 0.57%
32,657
+18,389
+129% +$2.62M
IOVA icon
48
Iovance Biotherapeutics
IOVA
$2.13B
$4.74M 0.55%
+102,157
New +$4.06M
MELI icon
49
Mercado Libre
MELI
$95.5B
$3.18M 0.37%
1,900
-3,100
-62% -$4.37M
VYX icon
50
NCR Voyix
VYX
$1.18B
$3.01M 0.35%
+130,400
New +$2.16M

Similar funds

DSAM Partners's Q4 2020 Portfolio in Review

As of Q4 2020, DSAM Partners held 70 positions worth $854M, up 48% from $578M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

DSAM Partners deployed $130M of net new capital in Q4 2020, opening 33 new positions and adding to 12 existing holdings. Its largest new stake was Micron Technology: 644,186 shares worth $48.4M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $24.8M trimmed.

  • DSAM Partners's largest Q4 2020 buy was Micron Technology: 644,186 shares worth $48.4M.
  • DSAM Partners added most to UnitedHealth in Q4 2020, an estimated $15M increase.
  • DSAM Partners's biggest Q4 2020 reduction was Meta Platforms (Facebook), cutting an estimated $24.8M.
  • DSAM Partners fully exited Alibaba in Q4 2020, selling an estimated $36.6M.
  • DSAM Partners's ten largest holdings make up 42% of its $854M portfolio in Q4 2020.
  • DSAM Partners opened 33 new positions and closed 12 in Q4 2020.
  • DSAM Partners's portfolio value rose 48% quarter-over-quarter to $854M.

Based on DSAM Partners's 13F filing for Q4 2020, filed 16 Feb 2021.